Although the primary endpoint was not met, axitinib was associated with significantly increased PFS and ORR for patients with previously-treated, advanced extrapancreatic neuroendocrine tumors.
Axitinib significantly increased PFS per BICR assessment and ORR both per investigator and BICR assessment compared with placebo, although the primary study end point was not met. Toxicity profile was ...
This segment addresses treatment planning after progression on second line therapy in progressive small bowel neuroendocrine tumor. Dr Lieu outlines common sequencing strategies following peptide ...
Moffitt Cancer Center will present results of the phase 3 NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77 Lu-DOTA 0-Tyr 3-Octreotate) in patients with ...
SAN FRANCISCO -- Adding a radioligand to standard therapy almost tripled median progression-free survival (PFS) in untreated high-grade gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a ...
T1 Tumor limited to the pancreas and size <2 cm T2 Tumor limited to the pancreas and size 2–4 cm T3 Tumor limited to the pancreas and size >4 cm or invading duodenum or bile duct T4 Tumor invading ...
Neuroendocrine tumors are a broad variety of tumor types that arise from neuroendocrine cells and are found throughout the body. They are most commonly found in the gastrointestinal tract, but can ...
Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results